For instance infliximab, an anti-TNF agent, has been demonstrated to offer benefits for the treatment of some autoimmune disorders, such as RA and AS [13],[14], but it fails or even exacerbates the condition in patients with other disorders such as MS [15]. This evidence concerns the gene TNF and myeloid sarcoma.